Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Barreiro

Showing results (191-200 of 220) with videos related to

Pageof 22
Sort By:
The Journal of Antimicrobial Chemotherapy|November 15, 2007
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trialVincent Soriano, Pilar García-Gasco, Eugenia Vispo, et al.
Antiviral Therapy|June 25, 2008
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavirEugenia Vispo, Pablo Barreiro, Juan A Pineda, et al.
Antiviral Therapy|April 9, 2008
Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcomeIvana Maida, Pilar Garcia-Gasco, Giovanni Sotgiu, et al.
AIDS (London, England)|July 12, 2013
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infectionKarin Neukam, Antonio Caruz, Antonio Rivero-Juárez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 12, 2006
Severe liver disease associated with prolonged exposure to antiretroviral drugsIvana Maida, Marina Núñez, Maria Jose Ríos, et al.
The Journal of Infectious Diseases|May 20, 2011
Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapyPablo Barreiro, Juan Antonio Pineda, Norma Rallón, et al.
AIDS (London, England)|May 4, 2011
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapsePablo Labarga, Pablo Barreiro, José A Mira, et al.
The Journal of Infectious Diseases|January 22, 2013
Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis virusesBruno Bezerril Andrade, Katherine Huppler Hullsiek, David R Boulware, et al.
Viruses|June 2, 2021
Virological Correlates of IgM-IgG Patterns of Response to SARS-CoV-2 Infection According to Targeted AntigensPablo Barreiro, Francisco Javier Candel, Juan Carlos Sanz, et al.
AIDS Research and Human Retroviruses|October 27, 2007
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI studyMatilde Sánchez-Conde, Rosario Palacios, José Sanz, et al.
Pageof 22

Showing results (191-200 of 220) with videos related to

Sort By:
Pageof 22
The Journal of Antimicrobial Chemotherapy|November 15, 2007
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trialVincent Soriano, Pilar García-Gasco, Eugenia Vispo, et al.
Antiviral Therapy|June 25, 2008
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavirEugenia Vispo, Pablo Barreiro, Juan A Pineda, et al.
Antiviral Therapy|April 9, 2008
Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcomeIvana Maida, Pilar Garcia-Gasco, Giovanni Sotgiu, et al.
AIDS (London, England)|July 12, 2013
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infectionKarin Neukam, Antonio Caruz, Antonio Rivero-Juárez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 12, 2006
Severe liver disease associated with prolonged exposure to antiretroviral drugsIvana Maida, Marina Núñez, Maria Jose Ríos, et al.
The Journal of Infectious Diseases|May 20, 2011
Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapyPablo Barreiro, Juan Antonio Pineda, Norma Rallón, et al.
AIDS (London, England)|May 4, 2011
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapsePablo Labarga, Pablo Barreiro, José A Mira, et al.
The Journal of Infectious Diseases|January 22, 2013
Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis virusesBruno Bezerril Andrade, Katherine Huppler Hullsiek, David R Boulware, et al.
Viruses|June 2, 2021
Virological Correlates of IgM-IgG Patterns of Response to SARS-CoV-2 Infection According to Targeted AntigensPablo Barreiro, Francisco Javier Candel, Juan Carlos Sanz, et al.
AIDS Research and Human Retroviruses|October 27, 2007
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI studyMatilde Sánchez-Conde, Rosario Palacios, José Sanz, et al.
Pageof 22